Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NeoGenomics (NEO) Stock Price & Analysis
1,742 Followers
NEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.03 - $21.22
Previous Close$14.51
Volume625.20K
Average Volume (3M)750.67K
Market Cap
$1.85B
Enterprise Value$2.08B
Total Cash (Recent Filing)$384.83M
Total Debt (Recent Filing)$608.18M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Jul 29, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding127,711,930
10 Day Avg. Volume818,077
30 Day Avg. Volume750,667
Standard Deviation0.17
R-Squared0.13
Alpha-0.00791
Financial Highlights & Ratios
Price to Book (P/B)46.88
Price to Sales (P/S)10.81
Price to Cash Flow (P/CF)-16.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit8.49
Enterprise Value/Ebitda-407.63
Forecast
1Y Price Target
$20.67Price Target Upside42.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
NeoGenomics News
PremiumPre-Earnings
Is NEO a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial PerformanceNEO delivered revenue of $156.2M, ahead of the Street’s $150M estimate, driven by both test volumes and a significant beat in average unit price.
Growth OutlookNEO lifted its long range projection to 10%+ for 2023-2028, driven by strong NGS growth.
Product LaunchesNEO intends to launch a NEO Comprehensive Liquid assay in the second half of the year for pharma and late fourth quarter to early first quarter in clinical.
Bears Say
Growth EstimatesPharma services or the Advanced Dx division of the company faced pressure, leading to a lowered estimate to flat growth for the year.
Legal IssuesThe US Appeals Court affirmed the lower court's decision to place a preliminary injunction on NEO's RaDaR sales due to patent infringement.
Management CommentaryThe 9% selloff in NEO's stock post its Q1 call is attributed to management's commentary that they're evaluating M&A, which the market interpreted to require dilutive financing.
---
Ownership Overview
11.69% Insiders
40.19% Mutual Funds
25.49% Other Institutional Investors
22.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $11.03 and its highest was $21.22 in the past 12 months.
What is NeoGenomics’s market cap?
Currently, no data Available
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Jul 29, 2024 which is in 7 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 30, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.02.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is >-$0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 127,711,930 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -8.541%.
Which hedge fund is a major shareholder of NeoGenomics?
Among the largest hedge funds holding NeoGenomics’s share is Royce & Associates LLC. It holds NeoGenomics’s shares valued at 9M.
---
NeoGenomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (42.45% Upside)
$20.67 (42.45% Upside)
Hedge Fund Trend
Decreased
By 797.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.71%
12-Months-Change
Fundamentals
Return on Equity
-8.88%
Trailing 12-Months
Asset Growth
-4.03%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Company Deck
---
NEO Earnings Call
Q1 2024
0:00 / 0:00
---
NEO Stock 12 Month Forecast
Average Price Target
$20.67
▲(42.45% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+2.02%
reiterated a buy rating 3 months ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +2.02% per trade.
---